Mon. 12 Feb 2024, 8:08am ET
Benzinga
Biotech, News, General
-Integrated summary of all previously published Phase 2a clinical results, together with the first peer reviewed publication of EEG and MRI results, substantially derisk the ongoing RewinD-LB Phase 2b trial of neflamapimod in dementia with Lewy bodies -
-RewinD-LB trial remains on track to complete enrollment in the first half of 2024 and report primary efficacy results in the second half of 2024-